Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupFRA:C1P 78 OCF Yield % is 11.69 as of Jul. 21, 2026, which is 29% below its 10-year median of 16.37. GuruFocus rates FRA:C1P with a GF Score™ of 78/100 and a GF Value™ of €0.92 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,005 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 83.48% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Consun Pharmaceutical Group OCF Yield % Explanation
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Consun Pharmaceutical Group OCF Yield % Related Terms
Consun Pharmaceutical Group OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group (FRA:C1P) has a OCF Yield % of 11.69 as of Jul. 21, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Consun Pharmaceutical Group and its competitors. This is 29% below median its historical median of 16.37. Over the past decade, Consun Pharmaceutical Group's OCF Yield % has ranged from 3.76 to 40.70. According to the industry distribution chart, Consun Pharmaceutical Group ranks #166 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 16.5%.
Is Consun Pharmaceutical Group's OCF Yield % too high?
Consun Pharmaceutical Group's current OCF Yield % of 11.69 is 29% below median its 10-year median of 16.37. Over the past 10 years, this metric has ranged from a low of 3.76 to a high of 40.70. The Drug Manufacturers industry median OCF Yield % is 3.62. Consun Pharmaceutical Group's value of 11.69 is 222.9% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #166 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #166 out of 1005 companies for OCF Yield %. This places Consun Pharmaceutical Group in the top 17% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 3.62. Consun Pharmaceutical Group's value of 11.69 is 222.9% above this benchmark. Historically, Consun Pharmaceutical Group's own OCF Yield % has ranged from 3.76 to 40.70 over the past decade. While the company's 10-year median is 16.37 vs. the industry median of 3.62, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.62, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current OCF Yield % of 11.69 is 222.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current OCF Yield % is 11.69, which is 29% below median its own 10-year median of 16.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (FRA:C1P) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.92, compared to a current price of €1.50 — trading 63% above its estimated fair value. The current OCF Yield % is 11.69, which is 29% below median its 10-year median of 16.37 and 222.9% above the Drug Manufacturers industry median of 3.62. Consun Pharmaceutical Group's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Consun Pharmaceutical Group (FRA:C1P), the current OCF Yield % is 11.69 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (FRA:C1P) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.50 is trading 63% above its estimated GF Value™ of €0.92.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for FRA:C1P:
OCF Yield %: 11.69 (29% below median its 10-year median of 16.37)
GF Value™: €0.92 vs. price of €1.50 (63% above fair value)
Industry Position: 222.9% above the Drug Manufacturers median (#166 of 1005)
No single metric tells the full story. See the FRA:C1P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
78GF Score
Get the complete analysis for FRA:C1P
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C1P has been successfully added to your 
